Skip to main content

Search This Blog

Pulmonary Hypertension

Posts

Group 3 Pulmonary Hypertension: From Bench to Bedside

Get link
Facebook
X
Pinterest
Email
Other Apps

October 21, 2026

Invalid Access Key! Invalid Access Key!

Hemoptysis: Diagnosis and Management

Get link
Facebook
X
Pinterest
Email
Other Apps

October 21, 2026

Invalid Access Key! Invalid Access Key!

HFpEF: Heart Failure with Preserved Ejection Fraction

Get link
Facebook
X
Pinterest
Email
Other Apps

October 17, 2026

Invalid Access Key! Invalid Access Key!

Pulmonary Vascular Dysfunctions in Cystic Fibrosis

Get link
Facebook
X
Pinterest
Email
Other Apps

October 17, 2026

Invalid Access Key! Invalid Access Key!

Abstract - 2026 - Pediatric Pulmonology

Get link
Facebook
X
Pinterest
Email
Other Apps

October 17, 2026

Invalid Access Key! Invalid Access Key!

HFpEF: Heart Failure with Preserved Ejection Fraction

Get link
Facebook
X
Pinterest
Email
Other Apps

October 13, 2026

Invalid Access Key! Invalid Access Key!

Group 3 Pulmonary Hypertension: From Bench to Bedside

Get link
Facebook
X
Pinterest
Email
Other Apps

October 13, 2026

Invalid Access Key! Invalid Access Key!

Powered by Blogger

Theme images by 4x6

Archive

October19
September59
August59
July47
June22
May41
April32
March70
February59
January81

Show more Show less

Popular posts from this blog

Afib: Causes, Symptoms, and Treatment Options

medical pah :: Article Creator As PAH Science Advances, Trial Design Comes Under Microscope Investigators are considering how best to interpret the results of potential new therapies. The science of pulmonary arterial hypertension (PAH) has advanced significantly in recent years. However, as the push for new and better therapies gains momentum, clinical trial investigators are thinking long and hard about how best to demonstrate and interpret patient improvement. One issue has to do with the question of which end points are best to meaningfully track patient responses to therapies. Marius Hoeper, MD, of Germany's Hannover Medical School, said in clinical practice, physicians tend to use a variety of measures to track patient improvement. "PH physicians usually take a holistic view," he said, "i.E., they consider the broad picture." That broad picture includes everything from patient's exercise capacity, assessed b...

Pulmonary Hypertension in Myelofibrosis: Risks and Treatments - www.oncnursingnews.com/

Pulmonary Hypertension in Myelofibrosis: Risks and Treatments - www.oncnursingnews.com/ Pulmonary Hypertension in Myelofibrosis: Risks and Treatments - www.oncnursingnews.com/ 4 Pulmonary Hypertension Programs Receive PHA's PHCC Accreditation - Benzinga Aria Raises $31M for Planned Study of Balloon Implant to Treat PAH - Pulmonary Hypertension News Pulmonary Hypertension in Myelofibrosis: Risks and Treatments - www.oncnursingnews.com/ Posted: 19 Mar 2020 08:53 AM PDT There may be certain factors that put a patient with myelofibrosis at a higher risk for pulmonary hypertension, according to Juan C. Lopez-Mattei, MD, FACC, FASE, FSCCT, FSCMR. Lopez-Mattei, a multimodality imaging cardiologist and associate professor of cardiology and diagnostic imaging at The University of Texas MD Anderson Cancer Center, was the lead author of an analysis that examined 143 patients with myelofibrosis who received an echocardiograp...

New ESC Pulmonary Hypertension Guidelines Urge Earlier Diagnosis - Medscape

September 21, 2022

New European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines for diagnosis and treatment of pulmonary hypertension have lowered the cutoff for defining pulmonary hypertension and tweaked the diagnostic algorithm so that the diagnosis is made earlier. The chairpersons, Marion Delcroix, MD, PHD from ERS and Stephan Rosenkranz, MD, from ESC presented the guidelines at the European Society of Cardiology (ESC) Congress 2022 and the document was simultaneously published online in the European Heart Journal. "Pulmonary hypertension is not a rare condition, since it affects approximately 1% of the global population and approximately 10% of the elderly population," said Rosenkranz, Cologne Cardiovascular Research Center, Cologne, Germany, in the guideline overview session.  With the new guidelines replacing the 2015 version, "we really help the physician to better diagnose and to diagnose earlier," Del...

Labels

"pulmonary hypertension prognosis" - Google News
idiopathic pulmonary hypertension
IFTTT
mild pulmonary hypertension
pulmonary artery hypertension
Pulmonary Hypertension
pulmonary hypertension causes
pulmonary hypertension diagnosis
pulmonary hypertension medications
pulmonary hypertension prognosis

pulmonary hypertension symptoms
pulmonary hypertension treatment
severe pulmonary hypertension
what is pulmonary hypertension

Show more Show less

yand